<DOC>
	<DOCNO>NCT02289820</DOCNO>
	<brief_summary>The goal study evaluate safety , tolerability immunogenicity ascend dos adjuvant combination single dosage level RSV sF adult 60 year old healthy stable , chronic underlie medical condition . This study also provide preliminary safety immunogenicity data support concurrent dose MEDI7510 influenza vaccine ( IIV ) , assess safety MEDI7510 dose previously assess Phase 1a study .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity MEDI7510 Older Adults</brief_title>
	<detailed_description>A Phase 1b , double-blind , randomize , control cohort escalation study evaluate safety , tolerability immunogenicity MEDI7510 . Approximately 264 subject enrol approximately 5 study center US randomize cohort ( Cohort 1 [ 4:1 ] ; Cohorts 2 3 [ 8:8:3 ] ; Cohort 4 [ 5:1 ] ) receive single intramuscular dose 1 study vaccine ( Cohorts 1 4 ) single intramuscular dose 2 study vaccine ( Cohorts 2 3 ) administer contralateral arm . Cohort 1 : MEDI7510 formulation ( n = 40 ) IIV ( n = 10 ) Cohort 2 : MEDI7510 formulation placebo ( n = 40 ) MEDI7510 formulation IIV ( n = 40 ) placebo IIV ( n = 15 ) Cohort 3 : MEDI7510 formulation placebo ( n = 40 ) MEDI7510 formulation IIV ( n = 40 ) placebo IIV ( n = 15 ) Cohort 4 : MEDI7510 formulation ( n = 20 ) IIV ( n = 4 )</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age great equal 60 year Ambulatory ambulatory assistance ( institutionalize , bedridden , homebound ) Weight great 90 lb Hemoglobin great equal 10.5 g/dL woman great equal 11 g/dL men Subject able complete followup period 360 day dose History allergy : component vaccine ; IIV intolerance IIV ; egg adulthood Receipt seasonal flu shot within 60 day prior dose Any unstable acute chronic medical condition , include one result change therapy ( medication ) 30 day prior randomization hospitalization previous year might predict result hospitalization year enrollment . Subjects severe , untreated uncontrolled underlying medical disease might either compromise subject safety affect ability ass safety investigational product exclude . Medications take asneeded basis permit start stop 30 day prior randomization unless medication previously take subject Clinically significant abnormality screen laboratory assessment screen ECG History hepatitis B hepatitis C infection History GuillainBarr√© syndrome Cognitive disorder inform consent obtain directly subject Previous vaccination RSV History current autoimmune disorder Immunosuppression cause disease , include human immunodeficiency virus ( HIV ) infection , medication . Any oral prednisone dose within 30 day enrollment plan dose within 360day followup period would disqualify . Expected need immunosuppressive medication 360day followup period would disqualify History splenectomy condition affect splenic function ( eg , hemoglobinopathy ) History cancer within precede 5 year treat nonmelanoma skin cancer Body Mass Index 40 high Receipt nonstudy vaccine within 30 day prior study dose expect receipt nonstudy vaccine within 30 day study dose Receipt investigational product 90 day prior randomization expect receipt investigational product period study followup Receipt immunoglobulin blood product within 4 month study dose ( 120 day ) expect receipt investigational product period study followup Current bleeding clot disorder include use anticoagulant drug antiplatelet activity ( nonsteroidal antiinflammatory drug , clopidogrel , ticagrelor aspirin ) Expected receipt antipyretic analgesic medication daily every day basis randomization 72 hour receipt IP ( Note : A daily dose aspirin consider contraindication enrollment . ) Subjects significant scarring , tattoo , abrasion , cut , infection deltoid region arm , investigator opinion , could interfere evaluation injection site local reaction Concurrent enrollment another clinical study involve invasive clinical procedure , include phlebotomy History alcohol drug abuse psychiatric disorder , investigator opinion , would affect subject 's safety compliance study Employees individual directly involve conduct study , individual involve conduct study , immediate family member individual</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>RSV</keyword>
	<keyword>Older adult</keyword>
	<keyword>MEDI7510</keyword>
	<keyword>Vaccine</keyword>
</DOC>